The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Minimal Residual Disease (MRD) Testing Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Flow Cytometry
1.2.3 Polymerase Chain Reaction
1.2.4 Next-generation Sequencing
1.2.5 Liquid Biopsies
1.3 Market by Application
1.3.1 Global Minimal Residual Disease (MRD) Testing Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Specialty Clinics
1.3.3 Hospitals
1.3.4 Research Institutions
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Minimal Residual Disease (MRD) Testing Market Perspective (2018-2029)
2.2 Minimal Residual Disease (MRD) Testing Growth Trends by Region
2.2.1 Global Minimal Residual Disease (MRD) Testing Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Minimal Residual Disease (MRD) Testing Historic Market Size by Region (2018-2023)
2.2.3 Minimal Residual Disease (MRD) Testing Forecasted Market Size by Region (2024-2029)
2.3 Minimal Residual Disease (MRD) Testing Market Dynamics
2.3.1 Minimal Residual Disease (MRD) Testing Industry Trends
2.3.2 Minimal Residual Disease (MRD) Testing Market Drivers
2.3.3 Minimal Residual Disease (MRD) Testing Market Challenges
2.3.4 Minimal Residual Disease (MRD) Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Minimal Residual Disease (MRD) Testing Players by Revenue
3.1.1 Global Top Minimal Residual Disease (MRD) Testing Players by Revenue (2018-2023)
3.1.2 Global Minimal Residual Disease (MRD) Testing Revenue Market Share by Players (2018-2023)
3.2 Global Minimal Residual Disease (MRD) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Minimal Residual Disease (MRD) Testing Revenue
3.4 Global Minimal Residual Disease (MRD) Testing Market Concentration Ratio
3.4.1 Global Minimal Residual Disease (MRD) Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Minimal Residual Disease (MRD) Testing Revenue in 2022
3.5 Minimal Residual Disease (MRD) Testing Key Players Head office and Area Served
3.6 Key Players Minimal Residual Disease (MRD) Testing Product Solution and Service
3.7 Date of Enter into Minimal Residual Disease (MRD) Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Minimal Residual Disease (MRD) Testing Breakdown Data by Type
4.1 Global Minimal Residual Disease (MRD) Testing Historic Market Size by Type (2018-2023)
4.2 Global Minimal Residual Disease (MRD) Testing Forecasted Market Size by Type (2024-2029)
5 Minimal Residual Disease (MRD) Testing Breakdown Data by Application
5.1 Global Minimal Residual Disease (MRD) Testing Historic Market Size by Application (2018-2023)
5.2 Global Minimal Residual Disease (MRD) Testing Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Minimal Residual Disease (MRD) Testing Market Size (2018-2029)
6.2 North America Minimal Residual Disease (MRD) Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Minimal Residual Disease (MRD) Testing Market Size by Country (2018-2023)
6.4 North America Minimal Residual Disease (MRD) Testing Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Minimal Residual Disease (MRD) Testing Market Size (2018-2029)
7.2 Europe Minimal Residual Disease (MRD) Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Minimal Residual Disease (MRD) Testing Market Size by Country (2018-2023)
7.4 Europe Minimal Residual Disease (MRD) Testing Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Minimal Residual Disease (MRD) Testing Market Size (2018-2029)
8.2 Asia-Pacific Minimal Residual Disease (MRD) Testing Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Minimal Residual Disease (MRD) Testing Market Size by Region (2018-2023)
8.4 Asia-Pacific Minimal Residual Disease (MRD) Testing Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Minimal Residual Disease (MRD) Testing Market Size (2018-2029)
9.2 Latin America Minimal Residual Disease (MRD) Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Minimal Residual Disease (MRD) Testing Market Size by Country (2018-2023)
9.4 Latin America Minimal Residual Disease (MRD) Testing Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size (2018-2029)
10.2 Middle East & Africa Minimal Residual Disease (MRD) Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size by Country (2018-2023)
10.4 Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sysmex Corporation
11.1.1 Sysmex Corporation Company Detail
11.1.2 Sysmex Corporation Business Overview
11.1.3 Sysmex Corporation Minimal Residual Disease (MRD) Testing Introduction
11.1.4 Sysmex Corporation Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.1.5 Sysmex Corporation Recent Development
11.2 Natera
11.2.1 Natera Company Detail
11.2.2 Natera Business Overview
11.2.3 Natera Minimal Residual Disease (MRD) Testing Introduction
11.2.4 Natera Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.2.5 Natera Recent Development
11.3 Asuragen
11.3.1 Asuragen Company Detail
11.3.2 Asuragen Business Overview
11.3.3 Asuragen Minimal Residual Disease (MRD) Testing Introduction
11.3.4 Asuragen Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.3.5 Asuragen Recent Development
11.4 Quest Diagnostics
11.4.1 Quest Diagnostics Company Detail
11.4.2 Quest Diagnostics Business Overview
11.4.3 Quest Diagnostics Minimal Residual Disease (MRD) Testing Introduction
11.4.4 Quest Diagnostics Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.4.5 Quest Diagnostics Recent Development
11.5 Mission Bio
11.5.1 Mission Bio Company Detail
11.5.2 Mission Bio Business Overview
11.5.3 Mission Bio Minimal Residual Disease (MRD) Testing Introduction
11.5.4 Mission Bio Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.5.5 Mission Bio Recent Development
11.6 LabCorp
11.6.1 LabCorp Company Detail
11.6.2 LabCorp Business Overview
11.6.3 LabCorp Minimal Residual Disease (MRD) Testing Introduction
11.6.4 LabCorp Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.6.5 LabCorp Recent Development
11.7 Guardant Health
11.7.1 Guardant Health Company Detail
11.7.2 Guardant Health Business Overview
11.7.3 Guardant Health Minimal Residual Disease (MRD) Testing Introduction
11.7.4 Guardant Health Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.7.5 Guardant Health Recent Development
11.8 NeoGenomics Laboratories
11.8.1 NeoGenomics Laboratories Company Detail
11.8.2 NeoGenomics Laboratories Business Overview
11.8.3 NeoGenomics Laboratories Minimal Residual Disease (MRD) Testing Introduction
11.8.4 NeoGenomics Laboratories Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.8.5 NeoGenomics Laboratories Recent Development
11.9 ARUP Laboratories
11.9.1 ARUP Laboratories Company Detail
11.9.2 ARUP Laboratories Business Overview
11.9.3 ARUP Laboratories Minimal Residual Disease (MRD) Testing Introduction
11.9.4 ARUP Laboratories Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.9.5 ARUP Laboratories Recent Development
11.10 NeoGenomics , Inc
11.10.1 NeoGenomics , Inc Company Detail
11.10.2 NeoGenomics , Inc Business Overview
11.10.3 NeoGenomics , Inc Minimal Residual Disease (MRD) Testing Introduction
11.10.4 NeoGenomics , Inc Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.10.5 NeoGenomics , Inc Recent Development
11.11 Opko Health
11.11.1 Opko Health Company Detail
11.11.2 Opko Health Business Overview
11.11.3 Opko Health Minimal Residual Disease (MRD) Testing Introduction
11.11.4 Opko Health Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.11.5 Opko Health Recent Development
11.12 Bio-Rad Laboratories
11.12.1 Bio-Rad Laboratories Company Detail
11.12.2 Bio-Rad Laboratories Business Overview
11.12.3 Bio-Rad Laboratories Minimal Residual Disease (MRD) Testing Introduction
11.12.4 Bio-Rad Laboratories Revenue in Minimal Residual Disease (MRD) Testing Business (2018-2023)
11.12.5 Bio-Rad Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details